目的 探讨鼻渊舒口服液联合西替利嗪滴剂治疗小儿过敏性鼻炎的疗效。方法 选取2018年1月-2020年1月在南阳市第二人民医院耳鼻咽喉科门诊治疗的过敏性鼻炎患儿108例为研究对象，随机分为对照组和治疗组，每组各54例。对照组患者口服西替利嗪滴剂，<6岁，0.5 mL/次，1次/d；≥ 6岁，1 mL/次，1次/d。治疗组在对照组基础上口服鼻渊舒口服液，<6岁，5 mL/次，3次/d，≥ 6岁，10 mL/次，3次/d。两组患儿均连续治疗10 d。观察两组的临床疗效和临床症状缓解时间。比较两组治疗前后血清学指标、免疫功能指标和血清炎性因子水平的变化情况。结果 治疗后，治疗组总有效率是94.44%，显著高于对照组81.48%（P<0.05）。治疗后，治疗组患儿的鼻塞、鼻痒、打喷嚏、流涕等临床症状缓解时间明显短于对照组（P<0.05）。治疗后，两组患儿免疫球蛋白（IgE）、肿瘤坏死因子α（TNF-α）、C反应蛋白（CRP）水平均显著降低（P<0.05）；治疗后，治疗组IgE、TNF-α、CRP水平显著低于对照组（P<0.05）。治疗后，两组患儿CD3⁺、CD4⁺、CD4⁺/CD8⁺指标均显著增加（P<0.05）；治疗后，治疗组这些免疫功能指标显著高于对照组（P<0.05）。治疗后，两组患儿血清白细胞介素4（IL-4）、白细胞介素17（IL-17）、γ干扰素（IFN-γ）、Th1/Th2水平均显著降低（P<0.05）；治疗后，治疗组血清炎性因子水平显著低于对照组（P<0.05）。结论 鼻渊舒口服液联合西替利嗪滴剂治疗小儿过敏性鼻炎临床效果显著，能有效缓解患儿的临床症状，可明显改善机体的免疫系统及炎性反应，具有一定的临床推广应用价值。

Objective To investigate the curative effect of Biyuanshu Oral Liquid combined with cetirizine in treatment of allergic rhinitis in children. Methods A total of 108 children with allergic rhinitis treated in the outpatient department of otorhinolaryngology of Nanyang Second General Hospital from January 2018 to January 2020 were selected as the research objects, and randomly divided into the control and the treatment group, with 54 children in each group. Children in the control group were po administered with Cetirizine Hydrochloride Drops, <6 years old, 0.5 mL/time, once daily; ≥ 6 years old, 1 mL/time, once daily. Children in the treatment group were po administered with Biyuanshu Oral Liquid on the basis of the control group, <6 years old, 5 mL/time, 3 times daily, ≥ 6 years old, 10 mL/time, 3 times daily. Both groups received continuous treatment for 10 d. The clinical efficacy and remission time of clinical symptoms in the two groups were observed. The changes of serological indexes, immune function indexes, and serum inflammatory factors before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 94.44%, significantly higher than that of the control group (81.48%, P<0.05). After treatment, the remission time of nasal congestion, nasal itching, sneezing, runny nose, and other clinical symptoms in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the levels of immunoglobulin (IgE), tumor necrosis factor (TNF-α), and C-reactive protein (CRP) were significantly decreased in both groups (P<0.05). After treatment, the levels of IgE, TNF-α, and CRP in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ were significantly increased in both groups (P<0.05). After treatment, these immune function indexes in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the levels of interleukin 4 (IL-4), interleukin 17 (IL-17), interferon (IFN-γ) and Th1/Th2 in the two groups were significantly decreased (P<0.05). After treatment, the level of these serum inflammatory factors in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Biyuanshu Oral Liquid combined with cetirizine has significant clinical effect in treatment of allergic rhinitis in children, and can effectively alleviate the clinical symptoms of children, and also can significantly improve the body's immune system and inflammatory response, which has certain clinical application value.

R987